Biogen (BIIB) Tops Q1 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Biogen Reports First Quarter 2016 Revenues of $2.7 Billion
April 21, 2016 7:15 AM EDTFirst quarter 2016 Non-GAAP diluted EPS rise 25%; GAAP diluted EPS rise 27%
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported first quarter 2016 financial results, including:
Total revenues of $2.7 billion, a 7% increase versus the same period in the prior year. Growth was driven by a 15% increase in worldwide TECFIDERA® revenues as well as increased revenues from ELOCTATE® and ALPROLIX®. Revenues were partially offset by a decrease in worldwide interferon sales. Foreign exchange, including a $26 million reduction in hedging gains, negatively impacted total revenues by approximately $50... More